Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients
The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Abstract
Background: The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) reduce serum cholesterol level and cardiovascular morbidity and mortality. However, the effect of statins on glucose metabolism is unclear. Some studies have suggested that statins may cause hyperglycemia by increasing calcium concentration in the islet cells leading to decrease in insulin release or by decreasing GLUT 4-mediated peripheral glucose uptake. Methods: We analyzed the data in 345,417 patients (mean age 61 ± 15 years, 94% males, 6% diabetic, 20% statin users) from the Veterans Affairs VISN 16 database. We studied change in fasting plasma glucose (FPG) in this population over a mean time of 2 years between the first available measurement and the last measurement form the most recent recorded visit. Data were limited to patients who had 2 FPG measurements. Diagnosis of diabetes had to be present before the first FPG measurement. Results: Among patients without diabetes, FPG increased with statin use from 98 mg/dL to 105 mg/dL, and among nonstatin users, FPG increased from 97 mg/dL to 101 mg/dL (increase in FPG with statin use P < 0.0001). Among patients with diabetes, FPG increased with statin use from 102 mg/dL to 141 mg/dL, and among nonstatin users, FPG increased from 100 mg/dL to 129 mg/dL (increase in FPG with statin use; P < 0.0001). After adjustment for age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, the change in FPG in nondiabetic statin users was 7 mg/dL (vs 5 mg/dL in nonstatin users, P < 0.0001) and for diabetic statin users it was 39 mg/dL (vs 32 in nonstatin users, P < 0.0001). Conclusions: Statin use is associated with a rise of FPG in patients with and without diabetes. This relationship between statin use and rise in FPG is independent of age and use of aspirin, β-blockers, and angiotensin-converting enzyme inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an elevation of liver enzymes, hyperglycaemia [53], new onset of diabetes mellitus type 2 [54] and proteinuria.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [53]
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Research works printed but not linked: 8
- Scandinavian Simvastatin Survival Study Group, 1994, Lancet, 344, 1383
- Collins R, 2003, Lancet, 361, 2005
- Colhoun HM, 2004, Lancet, 9435, 685
- Sabatine MS, 2004, Circulation, 110, S834
- Nakata M, 2006, Diabetologia, 49, 1881
- Sever PS, 2003, Lancet, 361, 1149
- 10.2337/dc05-1902 · doi:10.2337/dc05-1902
- Levitan EB, Arch Intern Med, 2147
Cited by
Items 101–126 of 126
Statins: Is There an Increased Risk of Diabetes?
Kolich, M. N., & Howard, P. A. (2012) · Hospital Pharmacy · doi:10.1310/hpj4707-513 · Cited by 2
Combined Effect of Metformin and Statin
Sabu, M. C., & Thekkekara, P. T. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100894 · Cited by 2
{"name":"Manjunath G Gandage", ". C., {"name":"Kukunuri Dinesh Kumar", ". C., {"name":"Paturu Venkatesh", ". C., & {"name":"Basavaraj Kesapur", ". C. (2022) · Future Journal of Pharmaceuticals and Health Sciences · doi:10.26452/fjphs.v2i4.330 · Cited by 2
Transitioning from population to individualized preventive cardiology
Morris, & Wright (2013) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s42829 · Cited by 1
Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia
Lyseng-Williamson, K. A., & Duggan, S. T. (2012) · Drugs & Therapy Perspectives · doi:10.1007/bf03262119 · Cited by 1
New Statin Labeling Requirements: An Overview
Hicks, M. R., & Murphy, B. L. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.742 · Cited by 1
THE ROLE OF PXR AND IKKβ SIGNALING IN CARDIOMETABOLIC DISEASE
Helsley, R. N. (2016) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2016.040 · Cited by 2
How has the treatment of hypercholesterolemia in Poland changed over the last six years?
Kapłon‐Cieślicka, A., Michalak, M., Kołtowski, Ł., & Filipiak, K. J. (2017) · Cardiology Journal · doi:10.5603/cj.a2017.0047 · Cited by 1
Medications affecting glycemic control
Korayem, G. B. (2017) · Integrative Clinical Medicine · doi:10.15761/icm.1000103 · Cited by 2
Statins and diabetes mellitus: risks and benefits
Drapkina, O. M., Корнеева, О. Н., & Sheptulina, A. F. (2012) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2012-6-85-90 · Cited by 3
Is it possible to improve long-term compliance of patients to statin therapy?
Soška, V., & Kyselák, O. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.129 · Cited by 3
Other Specific Types of Diabetes
Forlenza, G. P., Moran, A., & Nathan, B. M. (2018) · Europe PMC (PubMed Central) · Cited by 2
Management of Dyslipidemia after Stroke
Chang, Y., & Song, T. (2022) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2022.3.1 · Cited by 1
Kurosawa, K., Nakano, M., Yokoseki, I., Nagaoka, M., Takemoto, S., Sakai, Y., Kobayashi, K., Kazuki, Y., Fukami, T., & Nakajima, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.03.527063 · Cited by 1
Statins induce hyperglycaemia of uncertain importance
Montori, V. M., & Brito, J. P. (2012) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2012-101030
Effect of vitamin D on atorvastatin induced blood sugar changes in Wistar albino rats
Arunkumar, R., Meti, V., Ruckmani, A., & Devi, S. (2014) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20140420
Статины и риск развития сахарного диабета
Russian Federation (2012)
Effect of statins on the risk of new cases of diabetes
Шалаев, С. В., & Мидхатовна, С. З. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-3-54-57
Sherif, F. M. (2017) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2017.05.00116 · Cited by 1
Co wiadomo o diabetogennym działaniu statyn
Kłosiewicz−Latoszek, L., & Cybulska, B. (2013) · Via Medica Journals
Koh, K. K., & Quon, M. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.029
TYPE II DIABETES MELLITUS AND MANAGEMENT OF ISOLATED HYPERGLYCEMIA: A REVIEW
TELLO, J. D. C., MORETTA, D. E. S., HERNÁNDEZ, G. J. V., & Medina, L. S. H. (2022) · Innovare Journal of Health Sciences · doi:10.22159/ijhs.2022.v10i1.44968 · Cited by 1
Haldar, T., Oni‐Orisan, A., Hoffmann, T. J., Schaefer, C. A., Iribarren, C., Krauss, R. M., Medina, M. W., & RISCH, N. J. (2022) · Figshare · doi:10.6084/m9.figshare.20317453
Impact of statin therapy on glycemic status in diabetes-naïve patients: a systematic review
Arora, S., & Kohli, P. G. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20260353
Sari, D. E. D., Sari, E. A., Fitria, F., Hariyani, H., Seran, K. E., Fajriyah, S., Marhenta, Y. B., & Agustina, A. O. N. (2026) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v9i3.1481
Metadata
- Authors
- Sukhija, R., Prayaga, S., Marashdeh, M., Bursac, Z., Kakar, P., Bansal, D., Sachdeva, R., Kesan, S. H., & Mehta, J. L.
- Affiliations
- Division of Cardiovascular Medicine, Little Rock
- Central Arkansas Veterans Healthcare System (US)
- University of Arkansas for Medical Sciences (US)
- Venue
- Journal of Investigative Medicine
- Publisher
- SAGE Publications
- Published
- 2009-03
- Volume
- 57
- Issue
- 3
- Pages
- 495-499
- ISSN
- 1081-5589 (ISSN-L)
- 1708-8267
- OpenAlex
- W121422619
- Cited by
- 126
- References
- 20
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 10 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 7 · 2016: 10 · 2015: 11 · 2014: 12 · 2013: 12 · 2012: 15
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Investigative Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, fasting blood glucose, hyperglycemia, diabetes mellitus, glucose metabolism, veterans, insulin secretion, adverse drug reactions
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Fasting, Food Deprivation, Humans, Hypertension, Male, Middle Aged, United States, Veterans, Databases, Factual, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Complications, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.